Feasibility Study of Combination Chemotherapy with Paclitaxel, Doxorubicin and Cisplatin without Prophylactic Granulocyte Colony-stimulating Factor Injection for Intermediate-to-high risk or Recurrent Endometrial Cancer.
Feasibility Study of Combination Chemotherapy with Paclitaxel, Doxorubicin and Cisplatin without Prophylactic Granulocyte Colony-stimulating Factor Injection for Intermediate-to-high risk or Recurrent Endometrial Cancer.
复制标题
紫杉醇、阿霉素和顺铂联合化疗不注射预防性粒细胞集落刺激因子治疗中高危或复发性子宫内膜癌的可行性研究。
DOI：
10.1093/jjco/hyu124
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Fujiwara K.
中科院分区：
文献类型：
--
作者：
Nagao S;Nishikawa T;Hanaoka T;Kurosaki A;Iwasa N;Hasegawa K;Fujiwara K.
我们评估了紫杉醇，阿霉素和顺铂联合化疗的可行性，没有预防性粒细胞集落刺激因子注射中高危或复发性endometrial cancer.MethodsWomen组织学证实FIGO阶段I-II与>1/2子宫肌层浸润，III/IV期或复发性子宫内膜癌被招募。患者接受静脉内多柔比星（45 mg/m2），然后在第1天接受顺铂（50 mg/m2），在第2天接受静脉内紫杉醇（160 mg/m2）。根据第3天和第8天的中性粒细胞计数，给予格拉司琼（75 µg）。治疗每21天重复一次，持续6个周期或直至疾病进展或出现不可接受的毒性。主要终点为预定化疗的完成率;次要终点为3/4级毒性反应和可测量病灶患者的缓解率。ResultsFrom 2010年9月至2012年12月，35名妇女，其中7名FIGO I期，4名II期，13名III期，10名IV期和1名复发性子宫内膜癌，均入选。子宫内膜癌26例（1级16例，2级6例，3级4例），腺癌4例，浆液性腺癌2例，神经内分泌癌1例，低分化癌1例，混合癌1例。25例患者（71%）完成了6个化疗周期。34级血液学毒性包括全血细胞减少（97%）、血小板减少（6%）和贫血（34%）。3例患者（9%）发生了血小板减少性发热。在13例患者中观察到3/4级非血液学毒性。结论紫杉醇、阿霉素、顺铂联合化疗方案不预防性应用粒细胞集落刺激因子是可行的。
ObjectiveWe evaluated the feasibility of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high-risk or recurrent endometrial cancer.MethodsWomen with histologically confirmed FIGO Stages I–II with >1/2 myometrial invasion, Stage III/IV or recurrent endometrial cancer were enrolled. Patients received intravenous doxorubicin (45 mg/m2), followed by cisplatin (50 mg/m2) on Day 1 and intravenous paclitaxel (160 mg/m2) on Day 2. Granisetron (75 µg) was administered depending on neutrophil counts on Days 3 and 8. Treatment was repeated every 21 days for six cycles or until disease progression or unacceptable toxicity. The primary endpoint was the completion rate of the scheduled chemotherapy; secondary endpoints were Grade 3/4 toxicity and response rate in patients with measurable lesions.ResultsFrom September 2010 to December 2012, 35 women, including 7 with FIGO Stage I, 4 with Stage II, 13 with Stage III, 10 with Stage IV and 1 with recurrent endometrial cancer, were enrolled. There were 26 endometrial carcinomas (Grade 1, 16; Grade 2, 6; Grade 3, 4), 4 carcinosarcomas, 2 serous adenocarcinomas, 1 neuroendocrine carcinoma, 1 poorly differentiated carcinoma and 1 mixed carcinoma. Twenty-five patients (71%) completed six chemotherapy cycles. Grade 3/4 hematological toxicities included neutrocytopenia (97%), thrombocytopenia (6%) and anemia (34%). Three patients (9%) experienced neutropenic fever. Grade 3/4 non-hematological toxicities were observed in 13 patients. In 15 patients with evaluable lesions, the response rate was 80%.ConclusionsCombination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection is feasible.